Lower risk of gastrointestinal bleeding for apixaban

Lower risk of gastrointestinal bleeding for apixaban
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, according to a study published in the April issue of Gastroenterology.

Neena S. Abraham, M.D., from the Mayo Clinic in Scottsdale, Ariz., and colleagues conducted a retrospective study using administrative claims data of privately insured individuals and Medicare Advantage enrollees. Three propensity-matched cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban were created. Data were compared on rivaroxaban versus dabigatran for 31,574 patients; for apixaban versus dabigatran for 13,084 patients; and for apixaban versus rivaroxaban for 13,130 patients.

The researchers found that GI bleeding occurred more often in patients given rivaroxaban versus dabigatran (hazard ratio, 1.2). The risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban (hazard ratios, 0.39 and 0.33, respectively). For apixaban and rivaroxaban, the median times to were <90 days, while for dabigatran, the median time was <120 days.

"In a population-based study of receiving DOAC agents, we found apixaban had the most favorable GI safety profile and the least favorable profile " the authors write.


Explore further

Lower inpatient costs for dabigatran, rivaroxaban in A-fib

More information: Abstract
Full Text
Editorial
Journal information: Gastroenterology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Lower risk of gastrointestinal bleeding for apixaban (2017, April 10) retrieved 24 June 2019 from https://medicalxpress.com/news/2017-04-gastrointestinal-apixaban.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more